We’ve recently updated our valuation analysis.

MEI Pharma Valuation

Is MEIP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MEIP?

Other financial metrics that can be useful for relative valuation.

MEIP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does MEIP's PS Ratio compare to its peers?

The above table shows the PS ratio for MEIP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average20.2x
SLS SELLAS Life Sciences Group
40.5x60.1%US$40.5m
ATHX Athersys
3.7x-86.0%US$22.1m
AVTX Avalo Therapeutics
1.3x39.1%US$23.1m
ABEO Abeona Therapeutics
35.3x52.8%US$49.9m
MEIP MEI Pharma
0.5x-7.1%US$30.5m


Price to Earnings Ratio vs Industry

How does MEIP's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a
No more companies


Price to Sales Ratio vs Fair Ratio

What is MEIP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MEIP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ratio1.8x

Price-To-Sales vs Fair Ratio: MEIP is good value based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).


Share Price vs Fair Value

What is the Fair Price of MEIP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MEIP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.23
US$1.65
+620.8%
92.8%US$4.00US$0.10n/a4
Mar ’24US$0.22
US$1.72
+687.5%
80.0%US$4.00US$0.10n/a5
Feb ’24US$0.31
US$2.57
+733.3%
58.7%US$5.00US$0.40n/a6
Jan ’24US$0.24
US$2.90
+1,090.5%
67.1%US$6.00US$0.40n/a6
Dec ’23US$0.33
US$5.40
+1,551.4%
91.7%US$15.00US$0.40n/a6
Nov ’23US$0.35
US$5.21
+1,373.0%
87.6%US$15.00US$0.50n/a7
Oct ’23US$0.39
US$4.81
+1,144.8%
91.5%US$15.00US$0.50n/a8
Sep ’23US$0.50
US$4.81
+853.7%
91.5%US$15.00US$0.50n/a8
Aug ’23US$0.48
US$4.81
+904.7%
91.5%US$15.00US$0.50n/a8
Jul ’23US$0.58
US$4.81
+729.7%
91.5%US$15.00US$0.50n/a8
Jun ’23US$0.46
US$5.15
+1,024.2%
78.6%US$15.00US$0.50n/a10
May ’23US$0.49
US$5.30
+978.3%
74.5%US$15.00US$1.00n/a10
Apr ’23US$0.59
US$5.70
+864.3%
71.9%US$15.00US$1.00US$0.2310
Mar ’23US$2.07
US$9.90
+378.3%
41.8%US$20.00US$4.00US$0.2210
Feb ’23US$1.93
US$10.89
+464.2%
33.1%US$20.00US$7.00US$0.319
Jan ’23US$2.67
US$10.56
+295.3%
26.5%US$17.00US$7.00US$0.249
Dec ’22US$3.03
US$10.89
+260.0%
33.1%US$20.00US$7.00US$0.339
Nov ’22US$2.85
US$10.67
+274.3%
34.2%US$20.00US$7.00US$0.359
Oct ’22US$2.63
US$10.67
+305.6%
34.2%US$20.00US$7.00US$0.399
Sep ’22US$2.83
US$10.06
+255.3%
17.3%US$13.00US$7.00US$0.509
Aug ’22US$2.70
US$10.06
+272.4%
17.3%US$13.00US$7.00US$0.489
Jul ’22US$2.95
US$9.67
+227.7%
23.3%US$13.00US$5.50US$0.589
Jun ’22US$3.02
US$9.67
+220.1%
23.3%US$13.00US$5.50US$0.469
May ’22US$3.65
US$9.67
+164.8%
23.3%US$13.00US$5.50US$0.499
Apr ’22US$3.39
US$9.67
+185.2%
23.3%US$13.00US$5.50US$0.599


Discover undervalued companies